Those that prevent cardiovascular disease (primary prevention), those that treat an acute disease, and those that treat a chronic disease (secondary prevention)
There are both oral (taken by mouth) and intravenous (given through a vein) drugs that inhibit platelet function and are used to treat patients with cardiac and cerebrovascular diseases.
The class of antiplatelet drugs include:
Irreversible cyclooxygenase inhibitors Aspirin Triflusal (Disgren) Adenosine diphosphate (ADP) receptor inhibitors Clopidogrel (Plavix) Prasugrel (Effient) Ticagrelor (Brilinta) Ticlopidine (Ticlid) Phosphodiesterase inhibitors Cilostazol (Pletal) Protease-activated receptor-1 (PAR-1) antagonists Vorapaxar (Zontivity) Glycoprotein IIB/IIIA inhibitors (intravenous use only) Abciximab (ReoPro) Eptifibatide (Integrilin) Tirofiban (Aggrastat) Adenosine reuptake inhibitors Dipyridamole (Persantine) Thromboxane inhibitors Thromboxane synthase inhibitors Thromboxane receptor antagonists Terutroban
A platelet count of less than 135,000/µL in patients on antiplatelet therapy is predictive of both radiographic and clinical worsening. This is a clinically relevant target intended to help tailor and improve management in patients on antiplatelet therapy.